All In Biotech

Free tool

FAERS Monitor: Tzield

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761183 or its brand name (Tzield, Teplizumab-Mzwv). Reports on generic versions are filed under their own applications.

Reports

720

Serious

100

14% of reports

Hospitalization

33

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • rash166
  • nausea139
  • pyrexia120
  • fatigue119
  • vomiting92
  • headache86
  • lymphopenia62
  • lymphocyte count decreased55
  • chills51
  • rash pruritic44
  • pain42
  • pruritus41
  • alanine aminotransferase increased35
  • diarrhoea34
  • white blood cell count decreased34

Reports by year received

View as table
YearReports
202378
2024173
2025205
2026264

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,439 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
lymphopeniaSignal62128.6101.37,695
lymphocyte count decreasedSignal5591.270.74,805
rash pruriticSignal4423.717.8937
alanine aminotransferase increasedSignal3516.712.1501
chillsSignal5112.79.8542
rashSignal16611.19.71,552
pyrexiaSignal12010.18.6995
white blood cell count decreasedSignal349.26.6240
vomitingSignal925.74.7361
nauseaSignal1395.14.4476
fatigueSignal1194.53.8329
headacheSignal864.03.3197
pruritusSignal413.12.358
pain422.01.521
diarrhoea341.51.16

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.